BRCA1/2 mutations, including large genomic rearrangements, among unselected ovarian cancer patients in Korea

Authors
Do-Hoon KimChi-Heum ChoSun Young KwonNam-Hee RyooDong-Seok JeonWonmok LeeJung-Sook Ha
Department
Dept. of Laboratory Medicine (진단검사의학); Dept. of Obstetrics & Gynecology (산부인과학); Dept. of Pathology (병리학)
Issue Date
2018
Citation
Journal of Gynecologic Oncology, Vol.29(6) : e90-e90, 2018
ISSN
2005-0399
Abstract
Objective: We performed small-scale mutation and large genomic rearrangement (LGR) analysis of BRCA1/2 in ovarian cancer patients to determine the prevalence and the characteristics of the mutations. Methods: All ovarian cancer patients who visited a single institution between September 2015 and April 2017 were included. Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and long-range polymerase chain reaction (PCR) were performed to comprehensively study BRCA1/2. The genetic risk models BRCAPRO, Myriad, and BOADICEA were used to evaluate the mutation analysis. Results: In total, 131 patients were enrolled. Of the 131 patients, Sanger sequencing identified 16 different BRCA1/2 small-scale mutations in 20 patients (15.3%). Two novel nonsense mutations were detected in 2 patients with a serous borderline tumor and a large-cell neuroendocrine carcinoma. MLPA analysis of BRCA1/2 in Sanger-negative patients revealed 2 LGRs. The LGRs accounted for 14.3% of all identified BRCA1 mutations, and the prevalence of LGRs identified in this study was 1.8% in 111 Sanger-negative patients. The genetic risk models showed statistically significant differences between mutation carriers and non-carriers. The 2 patients with LGRs had at least one blood relative with breast or ovarian cancer. Conclusion: Twenty-two (16.8%) of the unselected ovarian cancer patients had BRCA1/2 mutations that were detected through comprehensive BRCA1/2 genetic testing. Ovarian cancer patients with Sanger-negative results should be considered for LGR detection if they have one blood relative with breast or ovarian cancer. The detection of more BRCA1/2 mutations in patients is important for efforts to provide targeted therapy to ovarian cancer patients.
Keywords
MutationGenesNeoplasmsOvaryKorea
URI
http://kumel.medlib.dsmc.or.kr/handle/2015.oak/41773
Appears in Collections:
1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Laboratory Medicine (진단검사의학)
1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Obstetrics & Gynecology (산부인과학)
1. Journal Papers (연구논문) > 1. School of Medicine (의과대학) > Dept. of Pathology (병리학)
Keimyung Author(s)
김도훈; 조치흠; 권선영; 류남희; 전동석; 이원목; 하정숙
Full Text
https://www.ejgo.org/DOIx.php?id=10.3802/jgo.2018.29.e90
File in this Item
oak-2018-1635.pdf(2.12 MB)Download
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE